Antitrust & Trade Regulation Health Intellectual Property

Read Antitrust & Trade Regulation updates, alerts, news, and legal analysis from leading lawyers and law firms:
News & Analysis as of

The Life Sciences Report - Spring 2014

In this issue: - A New Accelerator Takes Digital Health Start-Ups to the Next Level - The Return of the MedTech IPO Market - Is There a Deal in Your Future? A Guide to Navigating Antitrust Waters -...more

Advertising Law - Feb 13, 2014

FTC Drives Car-Related False Ad Suit to Settlement - The Federal Trade Commission recently settled charges with Nissan North America and its advertising agency over deceptive advertising for the Nissan Frontier pickup...more

IMS Study Shows Pro-Competitive Effects of Reverse Payment Settlement Agreements in ANDA Litigation

Earlier this month, the Generic Pharmaceutical Association (GPhA) held a press conference to announce the release of a study of the effects of reverse settlement payment agreements in ANDA litigation. ...more

Bloomberg Law: Actavis Court Requires Case-by-Case Analysis of Anticompetitive Effects of Reverse-Payment Settlements

This article analyzes the US Supreme Court's recent antitrust decision in FTC v. Actavis, which held that that courts should apply the rule of reason in analyzing reverse-payment settlements. ...more

Weekly eDiscovery Top Story Digest - June 26, 2013

Compiled by @ComplexD from online public domain resources, provided for your review/use is this week’s update of key industry news, views, and events highlighting key electronic discovery related stories, developments, and...more

Reverse-Payment Settlement Agreements Roundtable

Reverse-payment settlements between brand name and generic drug companies have remained a staple hot-button issue in the antitrust community for more than a decade. In some antitrust circles, simply mentioning the term...more

Par/Paddock Answers FTC Before Supreme Court

Par PharmaceuticalPar/Paddock, one of the generic drug company defendants in FTC v. Actavis Inc. et al. (the "reverse payment" ANDA settlement case now before the Supreme Court) filed its reponsive brief last week. In it,...more

La Governance della Spesa Farmaceutica H

Quadro macrofinanziario Analisi della normativa e dell'impianto regolatorio Proposte di riforma Aggiornato a Dicembre 2012...more

"The Global Competition Landscape: A Conversation With Sharis Pozen"

Skadden recently welcomed Sharis A. Pozen, former Acting Assistant Attorney General of the Antitrust Division of the U.S. Department of Justice, as a new partner in the firm’s Washington, D.C. office. Sharis discusses her DOJ...more

PPACA: What’s Next For Life Sciences Companies

Law360, New York (August 24, 2012, 12:57 PM ET) -- Life sciences companies breathed a sigh of relief when the U.S. Supreme Court largely upheld the Patient Protection and Affordable Care Act (PPACA). After all, the PPACA will...more

ANDA Automatic Stay of FDA Approval Does Not Defeat Standing in Sham Litigation Antitrust Counterclaim

The District of Delaware recently denied a motion to dismiss an antitrust counterclaim in a patent infringement action in the wake of defendant Mylan, Inc. ("Mylan") having filed an Abbreviated New Drug Application ("ANDA")...more

European Commission Finds “Pay For Delay” Deals On The Decline In Europe But Pharma Sector Antitrust Scrutiny Continues

On July 6, 2011 the European Commission (Commission) published the results of its second monitoring exercise of patent settlements in the pharmaceutical sector (Second Monitoring Report). The Commission notes “with...more

Trade Remedies Are Being Used to Combat Imports of Infringing Medical Devices

Medical device cases are being filed with increasing frequency at the U.S. International Trade Commission (ITC) to combat infringing imports. In particular, owners of intellectual property rights on medical devices regularly...more

Pricing e governance della spesa farmaceutica pubblica - Alcune proposte per una riforma organica che abbracci tutta la filiera

Fabio Pammolli e Nicola C. Salerno descrivono una proposta di rinnovamento complessivo della governance della spesa farmaceutica pubblica, con riferimento sia alla fascia "A" che alla fascia "H". I punti principali della...more

The ban on “pay to delay” pharma patent settlements: shaving health care costs, fighting anti-competition, and patents — all...

2 July 2010 – The U.S. House of Representatives has passed a measure banning patent settlements struck between brand-name and generic pharmaceutical companies to delay the release of generic drugs. The goal? To shave nearly...more

Antitrust: Commission confirms unannounced inspections in pharmaceutical sector

On 30 November 2010, European Commission officials carried out unannounced inspections at the premises of a number of pharmaceutical companies in several Member States. Reason was the Commission's suspicion that they may have...more

FTC Chair Calls for Ban to Pay-For-Delay Settlements

On January 13, 2010, the Federal Trade Commission released a study critical of “pay-for-delay” patent litigation settlements by which brand-name drug companies pay generic competitors to keep generic drugs off the market. The...more

Pharmaceutical Patent Settlements Under Fire on Both Sides of the Atlantic

In recent weeks, the pharmaceutical industry has been in the crosshairs of antitrust enforcers in the U.S. and in Europe. Specifically, patent litigation settlements in which a brand pharmaceutical manufacturer makes a...more

Reverse Payment Issue Continues to Sizzle

We reported recently that the issue of reverse settlement payments to generic drug manufacturers was continuing to heat up this summer. FTC Chairman Jon Leibowitz’s recent comments on the issue further support this forecast....more

The FTC's Continuing Challenge to Reverse Payment Patent Settlements in the Pharmaceutical Industry By Helen Cho Eckert

In early 2009, the Federal Trade Commission (‘‘FTC’’) launched its latest challenge to reverse payment settlements in the pharmaceutical industry, FTC v. Watson Pharmaceuticals (‘‘Watson’’).1 In a press release accompanying...more

The Latest Advance in the Debate Over Reverse Payment Settlements: Will the Supreme Court Punt, Again?

On April 24, 2009, a group of professors of law, economics and business, together with the American Antitrust Institute, the Public Patent Foundation, and AARP (collectively "amici") filed an amicus brief urging the Supreme...more

European Commission's Pharmaceutical Sector Inquiry Report Finds Certain Practices May Delay Entry of Generic Medicines

On November 28, 2008, the European Commission published its preliminary report and findings in connection with the sector inquiry it launched late last year on competition in the pharmaceutical sector. The Commission...more

Newsletter of the Advertising, Marketing & Media Practice Group of Manatt, Phelps & Phillips, LLP

IN THIS ISSUE: *FTC Study: Spending on Kid Marketing Much Lower Than Thought *Court Strikes Down Ban on Ads for Alcohol *Good-bye Scrabulous, Hello Wordscraper *COPA Struck Down Yet Again *Supermarkets Squabble Over...more

Newsletter of the Advertising, Marketing & Media Practice Group of Manatt, Phelps & Phillips, LLP

IN THIS ISSUE: *New York Orders Chain Restaurants to Post Calories *ICANN to Clamp Down on Domain Name Abuse *FTC Fines Internet Ad Company $200,000 *FTC Goes After Alleged MySpace Hijackers *It's Official:...more

European Commission Raids Pharmaceutical Companies to Start Sector Inquiry

On January 16, 2008, the European Commission launched a sector inquiry into the pharmaceuticals industry by carrying out a series of unannounced inspections of innovative and generic pharmaceutical companies. The targeted...more

26 Results
|
View per page
Page: of 2

Follow Antitrust & Trade Regulation Updates on: